A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression

Required: CD70 overexpression (IHC ≥2+)

CD70 expression in the tumor site of the subject meets the positive standard, that is, ≥2+

Must have received: standard treatment

have failed or cannot tolerate standard treatment

Cannot have received: CD70-targeted therapy

Patients who have received any treatment related to the CD70 target within 3 years

Cannot have received: experimental drug or device

Patients who have received any experimental drug treatment or used experimental devices within 28 days before CAR-T administration

Cannot have received: systemic anti-tumor treatment

Patients who have received any systemic anti-tumor treatment within 28 days or 5 half-lives (whichever is longer) before CAR-T administration, including systemic chemotherapy, immunotherapy, hormone therapy (excluding glucocorticoids), targeted therapy, systemic immunomodulators (including but not limited to interferon, interleukin 2 and tumor necrosis factor), and received Chinese herbal medicine or Chinese patent medicine with anti-tumor effects within 14 days before CAR-T administration

Cannot have received: radiotherapy

Patients who have received radiotherapy within three months before administration

Cannot have received: non-CD70 target cell therapy products

Patients who have received other non-CD70 target cell therapy products within two months before administration

Cannot have received: other cell therapy products

Patients who have received other cell therapy products in the past need to undergo RCL testing during the screening period, and patients with positive results in any test

Cannot have received: therapeutic glucocorticoids

Exception: physiological replacement doses allowed (e.g., prednisone ≤10 mg/day or equivalent)

Patients who have received therapeutic doses of glucocorticoids within 14 days before CAR-T administration (however, physiological replacement doses of glucocorticoids are allowed, such as 10 mg/day prednisone or equivalent)